NCT03123783 2023-12-26CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With NivolumabApexigen America, Inc.Phase 1/2 Completed140 enrolled 16 charts
NCT02482168 2023-12-20Study of the CD40 Agonistic Monoclonal Antibody APX005MApexigen America, Inc.Phase 1 Completed43 enrolled